Cargando…
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?
A growing number of clinical trials are documenting that adding a long-acting muscarinic antagonist (LAMA) to established asthma treatment with an inhaled corticosteroid (ICS) and a long-acting β(2)-agonist (LABA) is a treatment option that improves the health of patients with uncontrolled severe as...
Autores principales: | Cazzola, Mario, Rogliani, Paola, Matera, Maria Gabriella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322754/ https://www.ncbi.nlm.nih.gov/pubmed/37303017 http://dx.doi.org/10.1007/s40265-023-01897-2 |
Ejemplares similares
-
Treatable Mechanisms in Asthma
por: Cazzola, Mario, et al.
Publicado: (2021) -
Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease
por: Ora, Josuel, et al.
Publicado: (2020) -
Beyond Dual Bronchodilation – Triple Therapy, When and Why
por: Cazzola, Mario, et al.
Publicado: (2022) -
Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019) -
Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma
por: Aalbers, René, et al.
Publicado: (2017)